Effect of Zhisou Powder on Pulmonary Function and Inflammatory Markers in Patients with Small Airway Disease.
- Conditions
- Small Airway Disease
- Registration Number
- ITMCTR2000004099
- Lead Sponsor
- SHANTOU CENTRAL HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
1. More than 18 years old, male or female;
2. Meet the pulmmonary function criteria for small airway disease: MMEF, FEF50, FEF75 decreased, and more than 2 indicators were lower than 65% of the expected value;
3. Willing to take oral Chinese medicine treatment;
4. Able to communicate and write in language or text;
5. Sign the informed consent form voluntarily.
1. There are major diseases, such as lung malignant tumors, heart failure, renal failure, dementia, epilepsy, active tuberculosis, etc.;
2. Using respiratory drugs in past weeks,such as inhaled corticosteroids, anticholinergic drugs, ß2 receptor agonists, leukotriene receptor antagonists, etc.;
3. Currently in acute exacerbation of respiratory diseases, such as acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation of asthma, etc.;
4. Acute cardiovascular and cerebrovascular events (stroke, transient ischemic attack, acute coronary syndrome) in the past 3 months;
5. History of malignant tumors that are not completely cured;
6. Mental illness, drug addiction or alcoholism;
7. Lactation, pregnancy, or planned pregnancy in the near future;
8. History of allergy to Chinese medicinal materials, or unwillingness to take Chinese medicinal preparations;
9. Those who are not expected to cooperate or are not suitable for follow-up;
10. The informed consent is not signed.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pulmonary Function Test;
- Secondary Outcome Measures
Name Time Method Inflammation Biomarkers;Induced Sputum;Respiratory Questionnaire;